MedPath
HSA Approval

APO-NAPRO-NA TABLET 275 mg

SIN07136P

APO-NAPRO-NA TABLET 275 mg

APO-NAPRO-NA TABLET 275 mg

September 23, 1992

PHARMAFORTE SINGAPORE PTE LTD

PHARMAFORTE SINGAPORE PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPHARMAFORTE SINGAPORE PTE LTD
Licence HolderPHARMAFORTE SINGAPORE PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

**Dosage:** The recommended starting dose of naproxen sodium for adults is two 275 mg tablets followed by one 275 mg tablet every 6 to 8 hours, as required. The total daily dose should not exceed 5 tablets (1375 mg).

ORAL

Medical Information

**Indications:** For the relief of mild to moderately severe pain accompanied by inflammation in conditions such as musculoskeletal trauma and postdental extraction. Also indicated for the relief of pain associated with post partum cramping and dysmenorrhea.

**Contraindications:** Peptic ulcer or active inflammatory diseases of the gastrointestinal system. Known or suspected hypersensitivity to the drug. Naproxen sodium should not be used in patients in whom acute asthmatic attacks, urticaria, rhinitis or other allergic manifestations are precipitated by ASA or other nonsteroidal anti-inflammatory agents. Fatal anaphylactoid reactions have occurred in such individuals.

M01AE02

naproxen

Manufacturer Information

PHARMAFORTE SINGAPORE PTE LTD

APOTEX INC

Active Ingredients

NAPROXEN SODIUM

275 mg

Naproxen

Documents

Package Inserts

1.4.3 Proposed clean PI - Apo-Napro-NA (20 Oct 2021).pdf

Approved: November 25, 2021

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

APO-NAPRO-NA TABLET 275 mg - HSA Approval | MedPath